

# **Cell Therapy**

**Part II: Markets, Companies & Academic Institutions**

**By**

**Prof. K. K. Jain**  
MD, FRACS, FFPM  
**Jain PharmaBiotech**  
**Basel, Switzerland**

**November 2017**

**A Jain PharmaBiotech Report**

## **A U T H O R ' S   B I O G R A P H Y**

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 473 publications include 28 books (5 as editor + 22 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the 2017 version is included in a special report on gene therapy published by Jain PharmaBiotech. Other reports written by Prof. Jain have been published by PJB Publications, D & MD, Reuter's Business Insight, and Decision Resources Inc. Cell Therapy is one of the several in-house publications of Jain PharmaBiotech.

Prof. Jain's recent books include "Handbook of Nanomedicine" (1<sup>st</sup> ed by Springer 2008, Chinese ed by Peking University Press 2011, 2<sup>nd</sup> edition 2012, 3<sup>rd</sup> ed 2017 by Springer), "Textbook of Personalized Medicine" (1<sup>st</sup> ed by Springer 2009; Japanese edition 2012; 2<sup>nd</sup> ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2<sup>nd</sup> ed 2017), Handbook of Neuroprotection (Springer 2011), Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

**November 2017 (revised and published continuously since 2001)  
Copyright ©2017 by**

**Jain PharmaBiotech  
Bläsiring 7  
CH-4057 Basel  
Switzerland**

**Tel & Fax:       +4161-6924461  
Email:            info@pharmabiotech.ch  
Web site:        http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

# TABLE OF CONTENTS

<b>10. Markets and Future Prospects for Cell Therapy .....</b>	<b>6</b>
<b>Introduction.....</b>	<b>6</b>
<b>Methods for estimation of cell therapy markets .....</b>	<b>6</b>
<b>Potential markets for cell therapy.....</b>	<b>7</b>
Markets according to technologies.....	7
<i>Stem cell transplants .....</i>	<i>7</i>
<i>Supporting cell technologies .....</i>	<i>8</i>
<i>Blood transfusion market .....</i>	<i>8</i>
<i>Cord blood collection and storage.....</i>	<i>8</i>
Cell therapy and related technologies .....	8
Cell therapy markets according to therapeutic areas.....	8
<i>Bone and joint disorders .....</i>	<i>9</i>
<i>Cancer.....</i>	<i>9</i>
<i>Cardiovascular disorders .....</i>	<i>10</i>
<i>Diabetes mellitus .....</i>	<i>10</i>
<i>Liver disorders.....</i>	<i>11</i>
<i>Neurological disorders .....</i>	<i>11</i>
<i>Retinal degenerative diseases market .....</i>	<i>12</i>
<i>Skin and wound care .....</i>	<i>12</i>
<i>Urinary incontinence.....</i>	<i>12</i>
<i>Reconstruction of teeth by stem cell implants .....</i>	<i>12</i>
<b>Market size according to geographical areas .....</b>	<b>13</b>
<b>Unmet market needs in cell therapy .....</b>	<b>14</b>
<b>Drivers of growth of cell therapy markets.....</b>	<b>14</b>
Role of stem cells in regenerative medicine .....	14
Role of cells in markets for artificial organs .....	15
Increase of R&D expense on cell therapy .....	15
Increased used of cell-based drug discovery.....	15
Impact of emerging healthcare trends on cell therapy markets .....	15
Markets for cell therapy tourism.....	15
Involvement of pharmaceutical companies in cell therapy .....	16
<b>Future prospects of cell therapy .....</b>	<b>16</b>
Embryonic stem cell research around the world .....	16
Consortia for ESC research in Europe .....	17
<i>EuroStemCell.....</i>	<i>17</i>
<i>FunGenES .....</i>	<i>18</i>
<i>ESTOOLS .....</i>	<i>18</i>
<i>UK National Stem Cell Network .....</i>	<i>19</i>
Ethical concerns about commercialization of embryonic stem cells .....	20
Education of the physicians .....	20
Public education.....	20
NIH support of stem cell research .....	20
Funding of stem cell research from non-federal sources.....	21
Prospects of venture capital support for stem cell companies.....	22
Cell therapy in the developing countries.....	23
Guidelines for stem cell therapies.....	24
<b>Business strategies .....</b>	<b>24</b>
Formation of networks .....	25
Market potential of autologous vs allogeneic cells.....	25
Future market potential of adult vs embryonic stem cells .....	26
Transportation and handling of cell therapy products.....	26
Translating science into business .....	26
<b>11. Companies Involved in Cell Therapy .....</b>	<b>28</b>
<b>Introduction.....</b>	<b>28</b>
<b>Profiles of selected companies.....</b>	<b>30</b>
<b>Collaborations.....</b>	<b>359</b>
<b>12. Academic Institutions .....</b>	<b>368</b>
<b>Introduction.....</b>	<b>368</b>
<b>Stem cell center .....</b>	<b>368</b>
<b>Profiles of institutions.....</b>	<b>369</b>
<b>Collaborations.....</b>	<b>458</b>
<b>13. References .....</b>	<b>462</b>

## Tables

Table 10-1: Market size according to cell therapy and related technologies 2016-2026 .....	7
Table 10-2: Market size according to therapeutic areas for cell therapy in 2016-2026 .....	9
Table 10-3: Cell therapy markets for cardiovascular disorders in 2016-2026 .....	10
Table 10-4: Values of cell therapies for neurological disorders in 2016-2026 .....	11
Table 10-5: Total cell therapy market in 2016-2026 according to geographical areas .....	13
Table 10-6: Cord blood market according to geographical areas 2016-2026 .....	13
Table 10-7: Stem cells transplant market according to geographical areas 2016-2026.....	13
Table 10-8: SWOT Autologous cells vs allogeneic cells .....	25
Table 11-1: Publicly traded cell therapy companies .....	28
Table 11-2: Selected collaborations of cell therapy companies .....	359
Table 12-1: Therapeutic uses of stem cells.....	376
Table 12-2: Commercial collaborations of US academic institutes relevant to stem cells.....	458

## Figures

Figure 10-1: Unmet needs in cell therapy .....	14
--	----